She subsequently experienced one other psoriasis flare over 5 years since the end-of-study visit, during a phase II clinical trial for WHIM syndrome of the chemically distinct small-molecule CXCR4 antagonist mavorixafor (26). The gene discussed is CXCR4; the disease is psoriasis.